{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-000357","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2025-01-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.529171+00:00","generated_at":"2026-05-28T01:02:07.113045+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sunshine Biopharma appoints Michel Roy as Chief Commercial Officer","bullets":["Michel Roy appointed CCO effective Jan 13, 2025; initial base salary of $400,000 CAD annually.","Severance of $500,000 CAD payable if terminated without cause, plus minimum statutory notice.","Roy previously led Canadian ops of Shilpa Medicare (2020-2024) and was VP at Intas Pharmaceuticals (2014-2020).","Responsibilities include overseeing commercial strategy, sales, marketing, and business development."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-000357","json":"https://secwatch.observer/filing/0001683168-25-000357.json","markdown":"https://secwatch.observer/filing/0001683168-25-000357.md","text":"https://secwatch.observer/filing/0001683168-25-000357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316825000357/0001683168-25-000357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316825000357/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T01:02:07.113045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"59959e578e","claim":"Michel Roy was appointed as Chief Commercial Officer at Sunshine Biopharma Inc..","evidence_excerpt":"On January 13, 2025, Sunshine Biopharma Inc. (the “Company”) appointed Mr. Michel Roy as the Company’s Chief Commercial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316825000357/0001683168-25-000357-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Commercial Officer"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}